Literature DB >> 15196734

Clinical outcomes of stereotactic radiotherapy for stage I non-small cell lung cancer using a novel irradiation technique: patient self-controlled breath-hold and beam switching using a combination of linear accelerator and CT scanner.

Hiroshi Onishi1, Kengo Kuriyama, Takafumi Komiyama, Shiho Tanaka, Naoki Sano, Kan Marino, Satoshi Ikenaga, Tsutomu Araki, Minoru Uematsu.   

Abstract

We have developed a novel irradiation technique for lung cancer that combines a linear accelerator and CT scanner with patient-controlled breath-hold and radiation beam switching. We applied this technique to stereotactic three-dimensional (3D) conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) and evaluated the primary therapeutic outcomes. A total of 35 patients with stage I (15 IA, 20 IB) primary NSCLC (20 adeno, 13 squamous cell, and 2 others) were treated with this technique. Patients ranged from 65 to 92 years old (median, 78 years). Twenty-three (66%) patients were medically inoperable due to mainly chronic pulmonary disease or high age. Three-dimensional treatment plans were made using 10 different non-coplanar dynamic arcs. The total dose of 60 Gy was delivered in 10 fractions (over 5-8 days) at the minimum dose point in the planning target volume (PTV) using a 6 MV X-ray. After adjusting the isocenter of the PTV to the planned position by a unit comprising CT and linear accelerator, irradiation was performed under patient-controlled breath-hold and radiation beam switching. All patients completed the treatment course without complaint. Complete response (CR) and partial response (PR) rates were 8/35 (23%) and 25/35 (71%), respectively. Pulmonary complications of National Cancer Institute-Common Toxicity Criteria grade >2 were noted in three (9%) patients. During follow-up (range, 6-30 months; median, 13 months), two (6%) patients developed local progression and five (14%) developed distant or regional lymph node metastases. Two-year overall survival rates for total patients and medically operable patients were 58 and 83%, respectively. In conclusion, this new irradiation technique, utilizing patient-controlled radiation beam switching under self-breath-hold after precise alignment of the isocenter, allows safe high-dose stereotactic radiotherapy with sufficient margins around the CTV and reduced treatment times. Based on the initial results, excellent local control with minimal complications is expected for stage I NSCLC. Copyright 2004 Elsevier Ireland Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 15196734     DOI: 10.1016/j.lungcan.2004.01.004

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  20 in total

1.  A method for improved verification of entire IMRT plans by film dosimetry.

Authors:  Vesna Jacob; Peter Kneschaurek
Journal:  Strahlenther Onkol       Date:  2009-02-18       Impact factor: 3.621

2.  Deep inspiration breath-hold radiotherapy for lung cancer: impact on image quality and registration uncertainty in cone beam CT image guidance.

Authors:  Mirjana Josipovic; Gitte F Persson; Jens P Bangsgaard; Lena Specht; Marianne C Aznar
Journal:  Br J Radiol       Date:  2016-10-26       Impact factor: 3.039

Review 3.  Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis.

Authors:  Alexander Chi; Haiquan Chen; Sijin Wen; Haijuan Yan; Zhongxing Liao
Journal:  Radiother Oncol       Date:  2017-05-22       Impact factor: 6.280

4.  Influenza infection induces host DNA damage and dynamic DNA damage responses during tissue regeneration.

Authors:  Na Li; Marcus Parrish; Tze Khee Chan; Lu Yin; Prashant Rai; Yamada Yoshiyuki; Nona Abolhassani; Kong Bing Tan; Orsolya Kiraly; Vincent T K Chow; Bevin P Engelward
Journal:  Cell Mol Life Sci       Date:  2015-03-26       Impact factor: 9.261

5.  Computed tomography appearances of local recurrence after stereotactic body radiation therapy for stage I non-small-cell lung carcinoma.

Authors:  Satoshi Kato; Atsushi Nambu; Hiroshi Onishi; Akitoshi Saito; Kengo Kuriyama; Takafumi Komiyama; Kan Marino; Tsutomu Araki
Journal:  Jpn J Radiol       Date:  2010-05-29       Impact factor: 2.374

6.  Is diaphragm motion a good surrogate for liver tumor motion?

Authors:  Juan Yang; Jing Cai; Hongjun Wang; Zheng Chang; Brian G Czito; Mustafa R Bashir; Manisha Palta; Fang-Fang Yin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-09-12       Impact factor: 7.038

7.  Modified Glasgow Prognostic Score is predictive of prognosis for non-small cell lung cancer patients treated with stereotactic body radiation therapy: a retrospective study.

Authors:  Zhe Chen; Hotaka Nonaka; Hiroshi Onishi; Eiji Nakatani; Yoko Sato; Satoshi Funayama; Hiroaki Watanabe; Takafumi Komiyama; Kengo Kuriyama; Kan Marino; Shinichi Aoki; Masayuki Araya; Licht Tominaga; Ryo Saito; Yoshiyasu Maehata; Mitsuhiko Oguri; Masahide Saito
Journal:  J Radiat Res       Date:  2021-05-12       Impact factor: 2.724

8.  Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases.

Authors:  Peter Fritz; Hans-Jörg Kraus; Werner Mühlnickel; Udo Hammer; Wolfram Dölken; Walburga Engel-Riedel; Assad Chemaissani; Erich Stoelben
Journal:  Radiat Oncol       Date:  2006-08-20       Impact factor: 3.481

Review 9.  What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer.

Authors:  Alexander Chi; Sijin Wen; Zhongxing Liao; Jack Fowler; Jiahong Xu; Nam P Nguyen; James S Welsh; Ritsuko Komaki
Journal:  Biomed Res Int       Date:  2013-11-20       Impact factor: 3.411

10.  Clinical outcome of stereotactic body radiotherapy of 54 Gy in nine fractions for patients with localized lung tumor using a custom-made immobilization system.

Authors:  Masahiko Aoki; Yoshinao Abe; Hidehiro Kondo; Yoshiomi Hatayama; Hideo Kawaguchi; Akira Fujimori; Katsumasa Suzaki; Morio Seino; Takeshi Morita; Makoto Souma; Takao Tsushima; Shingo Takanashi
Journal:  Radiat Med       Date:  2007-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.